Study Finds Relacorilant May Extend Survival in Platinum-Resistant Ovarian Cancer Patients

Findings from Relacorilant Trial A clinical study has examined the use of relacorilant, a drug approved for Cushing’s syndrome, in treating platinum-resistant ovarian cancer.

The study included patients with platinum-resistant ovarian cancer. Participants received relacorilant alongside nab-paclitaxel, a standard chemotherapy, or nab-paclitaxel alone.

Patients receiving relacorilant were less likely to die from any cause compared to the control group.

The research provides evidence for potential new treatment protocols. Relacorilant works by blocking stress hormone receptors, which may help in cancer contexts beyond Cushing’s syndrome. Further trials may be needed to confirm these results across broader populations.

Study on Pembrolizumab In a parallel study, researchers assessed pembrolizumab, an immunotherapy drug, combined with standard care for platinum-resistant ovarian cancer. Pembrolizumab stimulates the immune system to target cancer cells.

The trial enrolled women with the condition. Patients receiving pembrolizumab plus standard care had improved survival compared to those on standard care alone.

The study team stated that the results support this combination as a potential standard of care.

Ovarian cancer affects thousands of women annually, with platinum resistance posing significant challenges to treatment. These studies highlight ongoing efforts to improve outcomes for affected patients. Regulatory bodies may review the data for approval expansions, potentially affecting access to these therapies.